当前位置： SCI文献检索 > GYNECOLOGIC ONCOLOGY期刊下所有文献 > Changes in health-related quality of life in older women after diagnosis with gynecologic cancer.

Changes in health-related quality of life in older women after diagnosis with gynecologic cancer.

Abstract：

PURPOSE:The impact of gynecologic cancer on health-related quality of life (HRQOL) is not fully understood. To our knowledge, this is the first longitudinal study to measure HRQOL changes from before to after gynecologic cancer diagnosis in older women. METHODS:Data were obtained from the Surveillance, Epidemiology, and End Results - Medicare Health Outcomes Survey database. Women aged 65 and older who were diagnosed with cervical, ovarian, or uterine cancer between baseline and follow-up surveys (n = 248; mean time from diagnosis = 12.54 ± 7.11 months) were propensity-matched to cancer-free controls (n = 1240). Logistic regression was used to assess risk of functional impairments and depressive symptoms at follow-up. Changes in HRQOL, as measured by the Medical Outcomes Study Short Form-36 and Veterans RAND 12-Item Survey, were estimated with mixed effects linear models. RESULTS:Women who were within 12 months of diagnosis and women diagnosed with regional/distant disease had significantly greater odds than controls of impairment at follow-up. HRQOL declines were greatest in those with advanced disease, with the most notable changes from baseline to follow-up observed for role limitations due to emotional problems (-8.60 vs. -3.42 in controls), general health (-7.76 vs 0.10), and physical functioning (-7.70 vs. -1.67). There were significant decreases in physical functioning and role limitations due to emotional problems for all cancer patients regardless of time since diagnosis. CONCLUSIONS:Gynecologic cancer has significant impacts on physical and mental aspects of HRQOL in older women. Interventions are needed to reduce pain, provide support, and prepare patients for changes in functioning and health.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Klapheke AK,Keegan THM,Ruskin R,Cress RD

doi

10.1016/j.ygyno.2019.11.033

subject

Has Abstract

pub_date

2020-02-01 00:00:00

pages

475-481

issue

2

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(19)31684-1

journal_volume

156

pub_type

杂志文章

相关文献

GYNECOLOGIC ONCOLOGY文献大全
  • Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.

    abstract：OBJECTIVE:Currently available tumor markers for ovarian cancer are still inadequate in both sensitivity and specificity to be used for population-based screening. Artificial neural network (ANN) as a modeling tool has demonstrated its ability to assimilate information from multiple sources and to detect subtle and comp...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.08.009

    authors： Zhang Z,Yu Y,Xu F,Berchuck A,van Haaften-Day C,Havrilesky LJ,de Bruijn HW,van der Zee AG,Woolas RP,Jacobs IJ,Skates S,Chan DW,Bast RC Jr

    更新日期：2007-12-01 00:00:00

  • Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.

    abstract：OBJECTIVE:Human papillomavirus (HPV) infection play a significant role in cervical carcinogenesis, and HPV oncoprotein E7 has important functions in the formation and maintenance of cervical cancers. Interleukin-12 (IL-12) has been reported to induce cellular immune responses, and has also been demonstrated to suppress...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2005.01.046

    authors： Jin HS,Park EK,Lee JM,NamKoong SE,Kim DG,Lee YJ,Jun HJ,Han BD,Bae SM,Ahn WS

    更新日期：2005-05-01 00:00:00

  • Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.

    abstract：OBJECTIVE:This study investigated the relationship between 13 proteins involved in DNA damage and the outcomes of patients with recurrent ovarian cancer (ROC). PATIENTS AND METHODS:Immunohistochemistry staining was performed in 114 diagnostic samples from patients with serous ROC who participated in the OVA-301 study,...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2013.10.032

    authors： Monk BJ,Kaye SB,Poveda A,Herzog TJ,Aracil M,Nieto A,Badri N,Parekh TV,Tanović A,Galmarini CM

    更新日期：2014-01-01 00:00:00

  • Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions.

    abstract：OBJECTIVE:Small cell carcinoma (SmCC) of the female genital tract constitutes a diagnostic and clinical challenge given its rarity and the lack of standardized therapeutic approaches. Here we review the morphological, clinical and molecular features of gynecologic SmCCs and discuss potential areas for future research. ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.ygyno.2014.05.017

    authors： Atienza-Amores M,Guerini-Rocco E,Soslow RA,Park KJ,Weigelt B

    更新日期：2014-08-01 00:00:00

  • Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions.

    abstract：OBJECTIVES:Data are lacking on how women view alternative approaches to surveillance for cervical cancer after treatment of high-grade cervical intraepithelial neoplasia. We measured and compared patient preferences (utilities) for scenarios with varying surveillance strategies and outcomes to inform guidelines and cos...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2010.05.002

    authors： Kuppermann M,Melnikow J,Slee C,Tancredi DJ,Kulasingam S,Birch S,Helms LJ,Bayoumi AM,Sawaya GF

    更新日期：2010-08-01 00:00:00

  • Society of Gynecologic Oncology recommendations for fellowship education during the COVID-19 pandemic and beyond: Innovating programs to optimize trainee success.

    abstract：:In approximately ten months' time, the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected over 34 million people and caused over one million deaths worldwide. The impact of this virus on our health, relationships, and careers is difficult to overstate. As the economic realiti...

    journal_title：Gynecologic oncology

    pub_type： 指南,杂志文章,评审

    doi：10.1016/j.ygyno.2020.10.009

    authors： Ferriss JS,Rose S,Rungruang B,Urban R,Spencer R,Uppal S,Sinno AK,Duska L,Walsh C

    更新日期：2021-01-01 00:00:00

  • Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.

    abstract：OBJECTIVE:Overexpression of the tyrosine kinase receptor erbB-2 is important in the pathogenesis of a variety of neoplasms including ovarian cancer. As a strategy to selectively eradicate erbB-2-overexpressing tumor cells, an anti-erbB-2 single-chain immunoglobin (sFv) gene was constructed to direct expression of intra...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1995.1260

    authors： Deshane J,Cabrera G,Grim JE,Siegal GP,Pike J,Alvarez RD,Curiel DT

    更新日期：1995-10-01 00:00:00

  • Association of obesity with survival in patients with endometrial cancer.

    abstract：BACKGROUND:Obesity confers an overall increased risk for development of endometrial cancer. However there are conflicting reports regarding the effect of obesity on patients' overall and disease specific survival. The purpose of this study was to evaluate the effect of obesity on survival in women with endometrial canc...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2019.03.258

    authors： Van Arsdale A,Miller DT,Kuo DY,Isani S,Sanchez L,Nevadunsky NS

    更新日期：2019-07-01 00:00:00

  • Phase I/II clinical safety studies of terameprocol vaginal ointment.

    abstract：OBJECTIVES:Terameprocol (M4N, EM-1421) is a novel transcription inhibitor that selectively interferes with HPV viral genes E6/E7 with Sp1-dependent promoters, and induces apoptosis by inactivation of the CDC2/cyclin B complex (maturation promoting factor) and production and phosphorylation of survivin. This trial was d...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2007.08.074

    authors： Khanna N,Dalby R,Tan M,Arnold S,Stern J,Frazer N

    更新日期：2007-12-01 00:00:00

  • Immune recognition of endometrial tumor antigens induced by multiparity.

    abstract：OBJECTIVE:The risk of developing endometrial cancer is reduced with increasing parity. The purpose of this study was to investigate the possibility that maternal immunization against fetal antigens might be elicited during pregnancy and, if so, to characterize antigens reactive with this immune response. METHODS:Sera ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1998.4988

    authors： Katsanis WA,Shields LB,Spinnato JA,Gerçel-Taylor C,Taylor DD

    更新日期：1998-07-01 00:00:00

  • Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival.

    abstract：OBJECTIVES:To determine the impact of venous thromboembolism (VTE) during primary treatment of ovarian clear cell carcinoma (OCCC) on survival. METHODS:After Institutional Review Board approval, 74 cases of OCCC were retrieved from our pathology files. Clinical and pathological data were obtained by medical record and...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2013.09.005

    authors： Diaz ES,Walts AE,Karlan BY,Walsh CS

    更新日期：2013-12-01 00:00:00

  • Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.

    abstract：OBJECTIVES:Early detection of ovarian cancer should improve overall survival. Multiple serum markers have been evaluated as possible tests to detect early stage disease, but few urine markers have been studied. Mesothelin has been detected in serum from patients with ovarian cancer, but has not been previously reported...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.04.022

    authors： Badgwell D,Lu Z,Cole L,Fritsche H,Atkinson EN,Somers E,Allard J,Moore RG,Lu KH,Bast RC Jr

    更新日期：2007-09-01 00:00:00

  • Predictive value of HPV DNA in lymph nodes in surgically treated cervical carcinoma patients--a prospective study.

    abstract：OBJECTIVE:High-risk types of HPV are etiological factors in cervical cancer. Lymph node involvement in cervical cancer patients reduces 5-year survival rates by 25-60%. However, the influence on survival of HPV DNA positivity in histopathologically negative lymph nodes remains unresolved. METHODS:The study included 11...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2006.10.018

    authors： Lukaszuk K,Liss J,Gulczynski J,Nowaczyk M,Nakonieczny M,Piatkowski M,Sliwinski W,Baay M,Wozniak I,Maj B,Lukaszuk M

    更新日期：2007-03-01 00:00:00

  • Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?

    abstract：BACKGROUND:Population-based studies of women with epithelial ovarian cancer suggest that black women have worse survival compared to white women. The primary objective of this study was to determine if, at a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center (CCC) serving a diverse racial and socioe...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2017.10.035

    authors： Dilley S,Erickson BK,Phillips CE,Kennemer CR,Zhang B,Matin T,Martin JY,Shah MM,Michael Straughn J Jr,Leath CA 3rd

    更新日期：2018-04-01 00:00:00

  • Is OVX1 a suitable marker for endometrial cancer?

    abstract：:The single most common cause leading to the diagnosis of endometrial cancer is postmenopausal bleeding. Although most patients with early-stage disease (FIGO stage I and II) can be cured, prognosis worsens considerably with increasing stage. While serum CA 125 levels are elevated only in a significant proportion of pa...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1997.4620

    authors： Beck EP,Wagner M,Anselmino L,Xu F,Bast RC Jr,Jaeger W

    更新日期：1997-05-01 00:00:00

  • Rectus abdominis myocutaneous flap for primary vaginal reconstruction.

    abstract：:Reconstructive procedures are being performed with increasing frequency in conjunction with pelvic exenterations and other radical gynecologic surgeries. The most common reconstructive procedures include continent urinary diversion, rectosigmoid anastomosis, and vaginal reconstruction. Historically, the gracilis myocu...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1993.1298

    authors： Carlson JW,Soisson AP,Fowler JM,Carter JR,Twiggs LB,Carson LF

    更新日期：1993-12-01 00:00:00

  • A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.

    abstract：OBJECTIVE:To develop a nomogram to predict overall survival (OS) in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. METHODS:A multicenter retrospective study was conducted. Potential prognostic variables included age; stage; grade; histology; performance status; residual disease; presenc...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2014.01.036

    authors： Previs RA,Bevis KS,Huh W,Tillmanns T,Perry L,Moore K,Chapman J,McClung C,Kiet T,Java J,Chan J,Secord AA

    更新日期：2014-03-01 00:00:00

  • Extra-peritoneal laparoscopic para-aortic lymphadenectomy--a prospective cohort study of 293 patients with endometrial cancer.

    abstract：OBJECTIVE:To determine if extra-peritoneal laparoscopic para-aortic (PA) lymphadenectomy allows a reliable assessment of PA nodes in patients with endometrial cancer (EC). METHODS:In October of 2005, a single surgeon began performing extra-peritoneal laparoscopic PA lymphadenectomy for patients with EC. A prospective ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2008.08.021

    authors： Dowdy SC,Aletti G,Cliby WA,Podratz KC,Mariani A

    更新日期：2008-12-01 00:00:00

  • Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.

    abstract：OBJECTIVES:In this study we evaluated changes in serum Müllerian inhibiting substance (MIS) concentration in a large number of patients with granulosa cell tumors (GCT) to determine whether MIS is elevated at the time of presentation and whether MIS is an index of successful surgical resection and management of recurre...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1998.5290

    authors： Lane AH,Lee MM,Fuller AF Jr,Kehas DJ,Donahoe PK,MacLaughlin DT

    更新日期：1999-04-01 00:00:00

  • Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin.

    abstract：OBJECTIVE:The goal of this work was to evaluate the involvement of gonadotropins in the regulation of adhesion of human epithelial ovarian carcinoma. We studied two pathways that were previously implicated in the metastatic implantation of ovarian carcinoma to the peritoneum, namely hyaluronan-CD44 and RGD-integrin med...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.2001.6512

    authors： Schiffenbauer YS,Meir G,Maoz M,Even-Ram SC,Bar-Shavit R,Neeman M

    更新日期：2002-02-01 00:00:00

  • Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.

    abstract：OBJECTIVE:Members of the glutathione S-transferase (GST) family have been shown to have functional polymorphisms that may affect drug metabolism and influence the effects of chemotherapy and survival from cancer. GSTM1, GSTT1, and GSTP1 genotypes were evaluated for their role in ovarian cancer treatment and survival. ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2005.08.035

    authors： Beeghly A,Katsaros D,Chen H,Fracchioli S,Zhang Y,Massobrio M,Risch H,Jones B,Yu H

    更新日期：2006-02-01 00:00:00

  • Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?

    abstract：OBJECTIVES:Women with advanced-stage, low-grade serous ovarian carcinoma (LGSC) have low chemotherapy response rates and poor overall survival. Most LGSC tumors overexpress hormone receptors, which represent a potential treatment target. Our study objective was to determine the outcomes of patients with advanced-stage ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2017.07.127

    authors： Fader AN,Bergstrom J,Jernigan A,Tanner EJ 3rd,Roche KL,Stone RL,Levinson KL,Ricci S,Wethingon S,Wang TL,Shih IM,Yang B,Zhang G,Armstrong DK,Gaillard S,Michener C,DeBernardo R,Rose PG

    更新日期：2017-10-01 00:00:00

  • Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.

    abstract：OBJECTIVE:Determine factors impacting the uptake of genetic counseling and results of genetic testing following universal tumor testing for Lynch syndrome in patients with endometrial cancer. METHODS:The study population consisted of two unselected cohorts of endometrial cancer patients, 408 identified retrospectively...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2014.06.009

    authors： Batte BA,Bruegl AS,Daniels MS,Ring KL,Dempsey KM,Djordjevic B,Luthra R,Fellman BM,Lu KH,Broaddus RR

    更新日期：2014-08-01 00:00:00

  • Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines.

    abstract：PURPOSE:A constituent of green tea, (-)-epigallocatechin-3-gallate (EGCG), has been known to possess anti-cancer properties. In this study, we investigated the time-course anticancer effects of EGCG on human ovarian cancer cells to provide insights into the molecular-level understanding of growth suppression mechanism ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2004.05.031

    authors： Huh SW,Bae SM,Kim YW,Lee JM,Namkoong SE,Lee IP,Kim SH,Kim CK,Ahn WS

    更新日期：2004-09-01 00:00:00

  • Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.

    abstract：OBJECTIVES:To refine models to predict surgical morbidity and 90-day mortality after primary debulking surgery (PDS) for advanced epithelial ovarian cancer (EOC). METHODS:Women with stage IIIC/IV EOC who underwent PDS with curative intent between 1/2/2003 and 12/30/2011 were included. Patient characteristics, intraope...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2015.10.025

    authors： Kumar A,Janco JM,Mariani A,Bakkum-Gamez JN,Langstraat CL,Weaver AL,McGree ME,Cliby WA

    更新日期：2016-01-01 00:00:00

  • The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma.

    abstract：OBJECTIVE:The hepatocyte growth factor (HGF) receptor c-Met plays an important role in tumor dissemination by activating mitogenic signaling pathways. The goal of this study was to investigate immunohistochemical (IHC) staining patterns of HGF and c-Met in endometrioid endometrial cancer (EC) and uterine serous cancer ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2010.11.031

    authors： Bishop EA,Lengyel ER,Yamada SD,Montag A,Temkin SM

    更新日期：2011-04-01 00:00:00

  • The impact of BMI on quality of life in obese endometrial cancer survivors: does size matter?

    abstract：BACKGROUND:Survivorship and quality of life issues are becoming increasingly relevant in endometrial cancer as a result of the marked increase in incidence of the disease combined with excellent and improving long term survival. OBJECTIVE:The purpose of this study was to evaluate the effect of obesity on quality of li...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2013.11.018

    authors： Smits A,Lopes A,Das N,Bekkers R,Galaal K

    更新日期：2014-01-01 00:00:00

  • Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).

    abstract：PURPOSE:To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum-resistant ovarian cancer in a real-world setting. PATIENTS AND METHODS:We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (wee...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2018.10.031

    authors： Lee JY,Park JY,Park SY,Lee JW,Kim JW,Kim YB,Jeong DH,Lee KB,Kim TH,Lee IH,Choi MC,Kim KH,Kim YM,Lee YJ,Kang S,KGOG Investigators.,Pujade-Lauraine E

    更新日期：2019-01-01 00:00:00

  • Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer.

    abstract：OBJECTIVES:To assess the utility of tumor diameter (TD) for predicting lymphatic dissemination (LD) and determining need for lymphadenectomy following diagnosis of endometrioid endometrial cancer. METHODS:Patients diagnosed with stage I-III endometrioid endometrial cancer during 2003-2013 who underwent pelvic or para-...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2016.02.017

    authors： Cox Bauer CM,Greer DM,Kram JJF,Kamelle SA

    更新日期：2016-05-01 00:00:00

  • Survival disparities in vulvar cancer patients in Commission on Cancer®-accredited facilities.

    abstract：OBJECTIVES:To investigate survival disparities and prognostic factors in vulvar cancer by age at diagnosis. METHODS:Women who underwent surgery and were diagnosed with stage I-IV vulvar cancer from 2004 to 2014 in the National Cancer Database were eligible. Proportions were compared using Chi-Square test. Survival was...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2019.11.025

    authors： Gaulin NB,Lesnock JL,Tian C,Osei-Bonsu K,Jacobs A,Richard SD,Krivak TC,Miller EM,Shriver CD,Casablanca Y,Maxwell GL,Darcy KM

    更新日期：2020-04-01 00:00:00